Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colorectal Cancer Policy Will Not Limit Current Off-Label Coverage, CMS Says

Executive Summary

The Centers for Medicare & Medicaid Services' national coverage determination for four colorectal cancer therapies will not limit coverage of other off-label indications, the agency said

You may also be interested in...



Medicare To Use Evidence Development For Off-Label Drug Use? CMS Guidance Unclear

CMS’ guidance on its “coverage with evidence development” policy for Medicare Part B does not elaborate on the scope of its application to off label drug use, only stating the agency could apply CED to drugs that have received FDA approval for at least one indication.

A Closer Look: Colorectal Cancer National Coverage Decision After One Year

Nearly a year after CMS finalized a contentious national coverage decision (NCD) on certain off-label uses of colorectal cancer drugs, five out of nine eligible clinical trials have yet to open for patient enrollment, according to the National Cancer Institute (NCI)

A Closer Look: Colorectal Cancer National Coverage Decision After One Year

Nearly a year after CMS finalized a contentious national coverage decision (NCD) on certain off-label uses of colorectal cancer drugs, five out of nine eligible clinical trials have yet to open for patient enrollment, according to the National Cancer Institute (NCI)

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel